GSK To Gain Fluviral Vaccine Through Acquisition Of ID Biomedical
This article was originally published in The Pink Sheet Daily
Executive Summary
GlaxoSmithKline plans to acquire ID Biomedical for $1.4 bil., a deal that could provide GSK with a second flu vaccine in the U.S. for the 2006/2007 flu season.
You may also be interested in...
GSK Plans U.S. Filing For Proprietary Adjuvant Pandemic Flu Vaccine In Early 2008
Vaccine also accepted for review in Europe.
GSK Plans U.S. Filing For Proprietary Adjuvant Pandemic Flu Vaccine In Early 2008
Vaccine also accepted for review in Europe.
GSK’s FluLaval Approval Raises Estimated Influenza Vaccine Doses To 115 Mil.
FluLaval is approved by FDA for immunization of adults against influenza Oct. 5.